Loading…
← CockpitCompetitor Analysis › IRD Opus Genetics, Inc.Open in the cockpit ↗

Opus Genetics, Inc.IRDCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum neutral 47
Mkt cap
$379M
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$4.09M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.8%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · USD$3.92
1D-3.2%
1W-9.1%
1M-2.2%
3M+5.4%
6M-22.1%
YTD+95.0%
1Y+99.0%
ATR %7.5%
Beta1.25
52w lowhigh32.5% off high

What Opus Genetics does

Employees: 28

Opus Genetics at a glance

Size Opus Genetics (IRD) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $379M, the 2877th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.92 on 18 Nov 2026.

Performance Over six months the shares fell 22.1%, against -22.7% for the median peer and -2.2% for the United States market (cap-weighted) — 10th highest of 19 in its peer set.

Growth Revenue fell 45.9% over the last twelve months (peer median +3.0%); the operating margin is -777.7% (peer median -2.2%).

Valuation It trades at 41.2× enterprise value to sales against a peer median of 4.4× (3rd most expensive of 18).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026IRD 79Peer median 77
Six months, rebased to 100: Opus Genetics against the median of its 20 peers (local-currency closes).

Opus Genetics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$7.91M$14.2M$11.0M$19.0M$39.9M
Revenue growth—+29%-42%-52%—
Gross profit$7.85M$14.1M$11.0M$19.0M$39.8M
EBITDA-$61.5M-$38.5M-$34.1M-$10.6M$18.2M
Net income-$137M-$49.6M-$57.5M-$9.99M$17.9M
Free cash flow-$48.7M-$35.3M-$25.6M-$1.11M$14.3M
Capital expenditure$189,000$0$0$0$0
Total debt$35.9M$1.13M$18.8M$0$0

Quarterly statements and history in the cockpit →

Opus Genetics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%4552688399002868PBYI459230053442CSPRY002872AVTX300452MPLT301111219A005690301089UNICHEMLABIRD6-month return →1-month return →
Up and to the right = strong over both horizons. Opus Genetics is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×25×50×75×4552688399002868PBYISHUKRAPHAR42C301111219A005690IRDRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Opus Genetics is the large dot.

Opus Genetics competitors and peer comparison

How Opus Genetics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Opus Genetics against its 20 peers (data as of 18 Nov 2026)
MeasureIRDPeer medianRank in peer set
1-month return-2.2%-14.0%3rd highest of 20
6-month return-22.1%-22.7%10th highest of 19
Distance from 52-week high-32.5%-43.3%8th highest of 21
Revenue growth (TTM)-45.9%+3.0%2nd lowest of 18
Operating margin-777.7%-2.2%3rd lowest of 19
EV / Sales41.2×4.4×3rd most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Opus Genetics IRDUnited States$379M-22%-46%-778%41.2×n/an/a
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%2.9×n/an/a
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%4.4×n/an/a
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%6.2×n/an/a
Puma Biotechnology PBYIUnited States$373M+3%+9%11%1.2×0.1%+0.3%
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%2.9×n/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%4.9×22.2%-15.7%
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a
Anhui Sunhere Pharmaceutical Excipients 300452.SZChina$388M-17%+9%19%2.2×-5.5%+12.2%
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
6467 6467.TWTaiwan$368Mn/an/a-2,618%1,407.9×n/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%7.2×n/an/a
Heartseed 219A.TJapan$392M+53%+197%9%21.9×46.5%+73.2%
Pharmicell 005690.KSSouth Korea$364M-55%+46%32%3.0×-7.9%+24.8%
Tuoxin Pharmaceutical 301089.SZChina$363M-28%+17%-20%5.3×n/an/a
Unichem Laboratories UNICHEMLAB.NSIndia$361M+28%+6%5%1.6×n/an/a
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%3.4×14.9%+13.7%

Questions

Which companies are Opus Genetics's closest peers?
The cockpit's peer set: JCR Pharmaceuticals (4552.T), Jiangsu Bioperfectus Technologies (688399.SS), Lifecome Biochemistry (002868.SZ), Puma Biotechnology (PBYI), SanBio (4592.T), Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), Shukra Pharmaceuticals (SHUKRAPHAR.NS), iX Biopharma (42C.SI).
Is Opus Genetics expensive compared with its peers?
On ev / sales it trades at 41.2× against a peer median of 4.4×, 3rd most expensive of 18 in its peer set.
How has Opus Genetics stock performed?
Over six months to 18 Nov 2026 the shares returned -22.1% against -22.7% for the median peer; over one year +99.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.